ALVINA CLARA FELIX
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina
19 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 19
conferenceObject DENGUE IN SOUTHEASTERN BRAZIL: A LARGE OUTBREAK FOLLOWED BY A THREE-YEAR LOW INCIDENCE PERIOD. OBSERVATIONS FROM A PROSPECTIVE COHORT STUDY(2018) LUNA, Expedito; FIGUEIREDO, Gerusa; LEVI, Jose; CAMPOS, Sergio; FIGUEIREDO, Walter; COSTA, Angela; FELIX, Alvina; SOUZA, Nathalia; PANNUTI, ClaudioconferenceObject ZIKA VIRUS INFECTION IN A COHORT STUDY TO ASSESS THE INCIDENCE OF DENGUE, STATE OF SAO PAULO, BRAZIL, 2015, 2016(2017) FIGUEIREDO, Gerusa M.; LUNA, Expedito J.; CARDOSO, Maria Regina; LEVI, Jose E.; FELIX, Alvina C.; SOUZA, Nathalia C. C.; SOUZA, Ana C.; CAMPOS, Sergio R. Campos R.; FIGUEIREDO, Walter M.; COSTA, Angela A.; PANNUTI, Claudio S.- Cross reactivity of commercial anti-dengue immunoassays in patients with acute Zika virus infection(2017) FELIX, Alvina Clara; SOUZA, Nathalia C. Santiago; FIGUEIREDO, Walter M.; COSTA, Angela A.; INENAMI, Marta; SILVA, Rosangela M. G. da; LEVI, Jose Eduardo; PANNUTI, Claudio Sergio; ROMANO, Camila MaltaSeveral countries have local transmission of multiple arboviruses, in particular, dengue and Zika viruses, which have recently spread through many American countries. Cross reactivity among Flaviviruses is high and present a challenge for accurate identification of the infecting agent. Thus, we evaluated the level of cross reactivity of anti-dengue IgM/G Enzyme-Linked Immunosorbent Assays (ELISA) from three manufacturers against 122 serum samples obtained at two time-points from 61 patients with non-dengue confirmed Zika virus infection. All anti-dengue ELISAs cross reacted with serum from patients with acute Zika infection at some level and a worrisome number of seroconversion for dengue IgG and IgM was observed. These findings may impact the interpretation of currently standard criteria for dengue diagnosis in endemic regions.
conferenceObject A COHORT STUDY TO DETERMINE THE INCIDENCE OF ZIKA VIRUS INFECTION AMONG NEWBORNS, SANTOS, BRAZIL, 2016-2017(2017) LUNA, Expedito J.; ROMANO, Camila M.; ARAUJO, Evaldo S.; LEVI, Jose E.; OLIVEIRA, Olimpia N.; FERNANDES, Luis R.; FELIX, Alvina C.; SOUZA, Nathalia S.; FERNANDES, Joao H.; CAMPOS, Sergio R.; FRAGOSO, Danielli B.; PANNUTI, Claudio S.- Zika and chikungunya virus infections in hematopoietic stem cell transplant recipients and oncohematological patients(2017) MACHADO, Clarisse Martins; PEREIRA, Barbara Brito de Souza; FELIX, Alvina Clara; OLIVEIRA, Maria Carolina; DARRIGO JR., Luiz Guilherme; SOUZA, Mair Pedro de; PATON, Eduardo Jose de Alencar; NEVES, Fabia; COLTURATO, Vergilio Rensi; SIMOES, Belinda PintoAedes mosquitoes are well adapted in domestic environments and widespread in tropical regions. Since 2015, Brazil has been experiencing a triple epidemic of dengue (DENV), chikungunya (CHKV), and Zika (ZIKV) viruses. The last 2 viruses are likely following the path of DENV, which has been endemic in most parts of the country since the 1980s. Given this triple epidemic, we proposed a prospective and collaborative study to assess the prevalence, morbidity, andmortality of DENV, CHKV, and ZIKV infections in hematopoietic stem cell transplant (HSCT) recipients and oncohematological patients. A case definition strategy (fever and rash) was used to prompt diagnostic investigation of DENV, ZIKV, and CHKV, which was accomplished by real-time polymerase chain reaction with plasma and urine samples. Clinical follow-up was performed 7 and 30 days after symptom onset. We report here the first cases of ZIKV and CHKV infections diagnosed in this ongoing study. From February to May 2016, 9 of the 26 patients (34.6%) fulfilling case definition criteria were diagnosed with DENV (3 cases), ZIKV (4 cases), or CHKV (2 cases) infections. Prolonged viremia and viruria were observed in dengue and Zika fever cases, respectively. Thrombocytopenia was the most frequent complication. Delayed engraftment was noted in 1 patient who acquired ZIKV 25 days before HSCT. All patients survived without sequelae. With the geographic expansion of arboviruses, donor and recipient screening may become mandatory. Patients living in areas where these viruses are not endemic are also at risk, since these viruses can be transmitted by blood as well as organ or tissue transplantation
- Enhanced detection of viral diversity using partial and near full-length genomes of human immunodeficiency virus Type 1 provirus deep sequencing data from recently infected donors at four blood centers in Brazil(2015) PESSOA, Rodrigo; WATANABE, Jaqueline Tomoko; CALABRIA, Paula; ALENCAR, Cecilia Salete; LOUREIRO, Paula; LOPES, Maria Esther; PROETTI, Anna Barbara; FELIX, Alvina Clara; SABINO, Ester C.; BUSCH, Michael P.; SANABANI, Sabri S.BackgroundHere, we report application of high-throughput near full-length genome (NFLG) and partial human immunodeficiency virus Type 1 (HIV-1) proviral genome deep sequencing to characterize HIV in recently infected blood donors at four major blood centers in Brazil. Study Design and MethodsFrom 2007 to 2011, a total of 341 HIV+ blood donors from four blood centers were recruited to participate in a case-control study to identify HIV risk factors and motivations to donate. Forty-seven (17 from SAo Paulo, eight from Minas Gerais, 11 from Pernambuco, and 11 from Rio de Janeiro) were classified as recently infected based on testing by less-sensitive enzyme immunoassays. Five overlapping amplicons spanning the HIV genome were polymerase chain reaction amplified from peripheral blood mononuclear cells. The amplicons were molecularly barcoded, pooled, and sequenced by a paired-end protocol (Illumina). ResultsOf the 47 recently infected donor samples studied, 39 (82.9%) NFLGs and six (12.7%) partial fragments were de novo assembled into contiguous sequences and successfully subtyped. Subtype B was the only nonrecombinant virus identified in this study and accounted for 62.2% (28/45) of samples. The remaining 37.8% (17/45) of samples showed various patterns of subtype discordance in different regions of HIV-1 genomes, indicating two to four circulating recombinant subtypes derived from Clades B, F, and C. Fourteen samples (31.1%) from this study harbored drug resistance mutations, indicating higher rate of drug resistance among Brazilian blood donors. ConclusionOur findings revealed a high proportion of HIV-1 recombinants among recently infected blood donors in Brazil, which has implications for future blood screening, diagnosis, therapy, and vaccine development.
- First phylogenetic analysis of dengue virus serotype 4 circulating in Espirito Santo state, Brazil, in 2013 and 2014(2018) VICENTE, C. R.; PANNUTI, C. S.; URBANO, P. R.; FELIX, A. C.; CERUTTI JUNIOR, C.; HERBINGER, K. -H.; FROESCHL, G.; ROMANO, C. M.The purpose of the present study was to reconstruct the phylogeny of dengue virus serotype 4 (DENV-4) that was circulating in Espirito Santo state, Brazil, in 2013 and 2014, and to discuss the epidemiological implications associated with this evolutionary hypothesis. Partial envelope gene of eight DENV-4 samples from Espirito Santo state were sequenced and aligned with 72 worldwide DENV-4 reference sequences from GenBank. A phylogenetic tree was reconstructed through Bayesian Inference and the Time of the Most Recent Common Ancestor was estimated. The study detected the circulation of DENV-4 genotype II in Espirito Santo state, which was closely related to strains from the states of Mato Grosso collected in 2012 and of Sao Paulo sampled in 2015. This cluster emerged around 2011, approximately 4 years after the entry of the genotype II in Brazil through its northern states, possibly imported from Venezuela and Colombia. This is so far the first phylogenetic study of the DENV-4 circulating in Espirito Santo state and shows the importance of an internal route of dengue viral circulation in Brazil to the introduction of the virus into this state.
- Saliva as a reliable sample for COVID-19 diagnosis in paediatric patients(2022) FELIX, Alvina C.; V, Anderson de Paula; RIBEIRO, Andreia C.; SILVA, Francini C. da; INEMAMI, Marta; COSTA, Angela A.; LEAL, Cibele O. D.; FIGUEIREDO, Walter M.; SARMENTO, Dmitry J. S.; SASSAKI, Tatiana A.; PANNUTI, Claudio S.; BRAZ-SILVA, Paulo H.; ROMANO, Camila Malta
- Use of saliva and RT-PCR screening for SARS-CoV-2 variants of concern: Surveillance and monitoring(2022) ZERBINATI, Rodrigo Melim; PALMIERI, Michelle; SCHWAB, Gabriela; FELIX, Alvina Clara; MARTINHO, Herculano; GIANNECCHINI, Simone; TO, Kelvin Kai-Wang; LINDOSO, Jose Angelo Lauletta; ROMANO, Camila Malta; BRAZ-SILVA, Paulo HenriqueGenomic surveillance has been applied since the beginning of the COVID-19 pandemic to track the spread of the virus, leading to the characterization of multiple SARS-CoV-2 variants, including variants of concern (VOC). Although sequencing is the standard method, a rapid molecular test for screening and surveillance of VOC is considered for detection. Furthermore, using alternative saliva as specimen collection facilitates the implementation of a less invasive, self-collected sample. In this study, we applied a combinatory strategy of saliva collection and reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 VOC detection. Saliva samples from patients attending a tertiary hospital with suspected COVID-19 were collected and SARS-CoV-2 RNA was detected using SARS-CoV-2 RT-qPCR reagent kit (PerkinElmer). Positive saliva samples were screened for SARS-CoV-2 VOC with previously described RT-PCR for Alpha, Beta, and Gamma variants. Saliva samples were positive in 171 (53%) of 324 tested. A total of 108 (74%) from positive samples were also positive for VOC by RT-PCR screening. Those samples were found between January and August 2021. This approach allowed us to successfully use an alternative and complementary tool to genomic surveillance to monitor the circulation of SARS-CoV-2 VOC in the studied population.
conferenceObject Evaluation of Clinical and Laboratory Response to Influenza and H1N1 Vaccines in a Group of Brazilian CVID Patients(2012) PEDRESCHI, Maira; OLIVEIRA, Ana Karolina Barreto; BARROS, Myrthes Toledo; COHON, Andrea; CELESTINO, A. T.; VILAS-BOAS, L. S.; FELIX, A. C.; PANNUTI, C. S.; KALIL, Jorge; KOKRON, Cristina M.CVID pts lack vaccine-specific ab production. We studied the clinical / laboratorial responses to influenza and H1N1 immunization in 22 CVID pts. Clinical evaluation was done through a score (infections, hospitalizations, antibiotic use). The score was applied during the previous and following year post immunization (PI). Blood was drawn before and 1/3/6/12 m PI. A significant reduction was observed in upper respiratory infections and sinusitis in the year PI (p<0.001), and 6 pts seroconverted. Statistical analysis showed no difference among ab levels before and PI. Among the 9 pts who presented H1N1 ab production, 4 reduced the clinical score. Of note, 50% of the 22 pts presented reduction of clinical scores. Then, although ab production to H1N1 wasn’t statistically significant, we observed a reduction in the number of infections in the year PI. This observation may be due to eventual presence of influenza’sabs but reinforces potential benefits of vaccination in CVID pts.